StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.34−0.23 (-4.04%)

Close on Nov 18, 2026Market cap $463.35MP/E –Yield –

Valneva cash

Cash and short-term investments held at the end of each period.

Valneva's cash was €121.53M at Jun 30, 2026. For fiscal 2025 it was €109.65M, down 34.8% from the year before. The highest annual figure on record is €346.69M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025€109.65M-34.8%
FY2024Dec 31, 2024€168.27M+33.5%
FY2023Dec 31, 2023€126.08M-56.0%
FY2022Dec 31, 2022€286.53M-17.4%
FY2021Dec 31, 2021€346.69M+69.6%
FY2020Dec 31, 2020€204.44M+217.3%
FY2019Dec 31, 2019€64.44M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€121.53M-24.7%
Q1 FY2026Mar 31, 2026€105.27M-31.2%
Q4 FY2025Dec 31, 2025€109.65M-34.8%
Q3 FY2025Sep 30, 2025€143.46M-8.2%
Q2 FY2025Jun 30, 2025€161.31M+22.7%
Q1 FY2025Mar 31, 2025€152.99M-13.4%
Q4 FY2024Dec 31, 2024€168.27M+33.5%
Q3 FY2024Sep 30, 2024€156.34M-8.7%
Q2 FY2024Jun 30, 2024€131.41M-35.7%
Q1 FY2024Mar 31, 2024€176.64M-30.6%
Q4 FY2023Dec 31, 2023€126.08M-56.0%
Q3 FY2023Sep 30, 2023€171.25M-34.4%
Q2 FY2023Jun 30, 2023€204.41M-39.2%
Q1 FY2023Mar 31, 2023€254.49M-18.2%
Q4 FY2022Dec 31, 2022€286.53M-17.4%
Q3 FY2022Sep 30, 2022€261.04M+5.3%
Q2 FY2022Jun 30, 2022€336.23M+2.0%
Q1 FY2022Mar 31, 2022€311.26M+31.9%
Q4 FY2021Dec 31, 2021€346.69M+69.6%
Q3 FY2021Sep 30, 2021€247.95M+284.8%
Q2 FY2021Jun 30, 2021€329.77M–
Q1 FY2021Mar 31, 2021€235.91M–
Q4 FY2020Dec 31, 2020€204.44M–
Q4 FY2019Dec 31, 2019€64.44M–

More Valneva figures

See a number that looks wrong?